Body Composition Analyzers Market Size, Share, Trends, and Industry Analysis - Global Forecast to 2036 | GLP-1 Monitoring and Clinical Adoption Drive Market Toward USD 4.13 Billion
Dublin, Oct. 28, 2026 (GLOBE NEWSWIRE) -- "Body Composition Analyzers Market Size, Share, and Industry Analysis - Global Forecast to 2036" has been added to ResearchAndMarkets.com's offering.
The global body composition analyzers market was valued at USD 1.80 billion in 2025 and is estimated to reach USD 1.95 billion in 2026. The market is projected to grow at a CAGR of 7.8% during 2026-2036, reaching USD 4.13 billion by 2036. The report evaluates market technologies, clinical evidence, regulatory and reimbursement conditions, pricing, competitive strategies, and demand across healthcare, fitness, research, and consumer applications.
The analysis covers bioelectrical impedance analysis (BIA), dual-energy X-ray absorptiometry (DXA), air displacement plethysmography, 3D optical body scanning, skinfold calipers & other manual tools, and consumer smart scales. The BIA category includes single-frequency, multi-frequency, segmental, and spectroscopy systems. Wearables not primarily intended for body composition measurement are excluded.
Clinical Demand and Market Growth Drivers
Demand for body composition analyzers is increasing as healthcare providers move beyond BMI and place greater emphasis on direct adiposity and muscle mass assessment. In January 2025, a Commission in The Lancet Diabetes & Endocrinology, supported by more than 75 medical organizations, recommended using BMI as a screening measure and confirming excess body fat through an additional method such as waist measurement, bioimpedance, or DXA. The American Medical Association's 2023 policy addressing the limitations of BMI further supports this transition.
Rapid adoption of GLP-1 medicines is creating another significant growth opportunity. DXA findings from the STEP 1 semaglutide trial indicated that approximately 39% of weight lost was lean mass, highlighting the need to monitor both fat and muscle during obesity treatment. U.S. GLP-1 prescriptions recorded in the Epic Cosmos database exceeded 1.4 million in 2025, compared with fewer than 4,600 in 2018. Eli Lilly also reported USD 36.5 billion in 2025 sales from its tirzepatide products, demonstrating the scale of the expanding obesity treatment market.
Aging populations are strengthening demand for sarcopenia, malnutrition, and clinical nutrition assessment. The World Health Organization expects one in six people worldwide to be aged 60 or older by 2030. Clinical recommendations supporting DXA or BIA for muscle mass measurement are expected to increase adoption in hospitals, geriatric care, nutrition services, and primary care.
Market Restraints and Emerging Opportunities
Market growth remains constrained by variations in BIA accuracy associated with hydration, food intake, exercise, body fat level, and device-specific prediction equations. Limited standardization across technologies and insufficient validation among diverse ethnic groups, age ranges, and body sizes also affect clinical confidence. Additional barriers include unclear treatment thresholds, implanted cardiac devices, edema, DXA table limits, and restricted reimbursement.
In the U.S., whole-body BIA is billed under Category III code 0358T, which is frequently not covered by payers. Low-priced smart scales and connected wearables also place pricing pressure on professional systems. Regulatory and data privacy requirements are raising compliance costs, as demonstrated by the FDA warning issued to WHOOP in July 2025 and the FTC's 2024 update to its Health Breach Notification Rule.
High-growth opportunities include monitoring patients enrolled in obesity drug programs, integrating connected analyzers with remote care platforms, and supporting clinical trials for muscle-preserving therapies. Point-of-care BIA is also positioned for wider primary care adoption because it is more accessible than DXA. Other key trends include bioimpedance-enabled wearables, AI-based 3D optical scanning, cloud connectivity, electronic health record integration, and broader use of fat and lean mass endpoints in obesity research.
Segment Outlook
Regional Market Analysis
North America is expected to remain the leading body composition analyzers market in 2026, supported by high obesity prevalence, rapid GLP-1 adoption, a large fitness industry, and strong consumer spending on connected health products. Limited reimbursement and FDA and FTC oversight will continue to influence product positioning and market access.
Europe holds a significant share, supported by sarcopenia guidelines, established healthcare systems, and regional manufacturers including seca, Withings, COSMED, Akern, and Bodystat. Products marketed in the region must comply with the EU Medical Device Regulation and GDPR.
Asia-Pacific is forecast to achieve the highest regional CAGR through 2036. Growth is driven by rising obesity and diabetes rates, aging populations, increased awareness of body fat risks, and strong manufacturers including InBody, Samsung, Tanita, Omron Healthcare, and Xiaomi. Latin America is benefiting from a large fitness market and expanding clinical adoption, while the Middle East & Africa is supported by preventive health investment and high obesity rates in Saudi Arabia, the UAE, Kuwait, and Qatar.
Competitive Landscape
The body composition analyzers market remains fragmented across professional BIA manufacturers, medical imaging companies, air displacement and 3D scanning specialists, consumer electronics brands, and medtech companies serving dialysis and lymphedema care. Competition is based on validated accuracy, software capabilities, connectivity, regulatory clearances, usability, pricing, and brand reputation.
Companies profiled in the report include InBody Co., Ltd., Tanita Corporation, seca GmbH & Co. KG, COSMED S.r.l., Akern S.r.l., Bodystat Ltd., RJL Systems, Inc., Charder Electronic Co., Ltd., SELVAS Healthcare, Inc., Hologic, Inc., GE HealthCare Technologies Inc., Fresenius Medical Care AG, ImpediMed Limited, Omron Healthcare Co., Ltd., Withings, Garmin Ltd., Xiaomi Corporation, and Samsung Electronics Co., Ltd.
The report provides market size estimates and forecasts through 2036, identifies high-growth technologies and applications, evaluates regulatory and reimbursement barriers, and benchmarks leading companies. It supports product development, clinical positioning, investment planning, partnership strategies, and channel decisions for manufacturers, healthcare providers, pharmaceutical companies, CROs, and investors.
Key Topics Covered
1. Introduction
1.1. Market Definition
1.2. Market Ecosystem
1.3. Currency and Limitations
1.3.1. Currency
1.3.2. Limitations
1.4. Key Stakeholders
2. Research Methodology
2.1. Research Approach
2.2. Data Collection & Validation Process
2.2.1. Secondary Research
2.2.2. Primary Research & Validation
2.2.2.1. Primary Interviews with Industry Experts
2.2.2.2. Country-/Region-Level Analysis
2.3. Market Estimation
2.3.1. Bottom-Up Approach (Installed Base and Unit Shipments x Average Selling Price)
2.3.2. Top-Down Approach (Share of Medical Device and Consumer Health Device Revenues)
2.3.3. Forecast Methodology
2.4. Data Triangulation
2.5. Assumptions
3. Executive Summary
4. Market Overview
4.1. Introduction
4.2. Market Dynamics
4.2.1. Drivers
4.2.1.1. Shift from BMI Toward Direct Measurement of Body Fat
4.2.1.2. Monitoring Body Composition During GLP-1 Therapy
4.2.1.3. Growing Clinical Focus on Sarcopenia and Malnutrition
4.2.2. Restraints
4.2.2.1. Accuracy Limitations of Bioelectrical Impedance Devices
4.2.2.2. Limited Reimbursement for Body Composition Testing
4.2.2.3. Price Competition from Low-Cost Consumer Devices
4.2.2.4. Regulatory and Data Privacy Requirements for Connected Health Products
4.2.3. Opportunities
4.2.3.1. Body Composition Monitoring in Obesity Pharmacotherapy Programs
4.2.3.2. Clinical Trial Endpoints for Muscle-Preserving Therapies
4.2.3.3. Point-of-Care Assessment in Primary Care
4.2.4. Challenges
4.2.4.1. Lack of Standardization Across Devices and Algorithms
4.2.4.2. Validating Measurements Across Diverse Populations
4.2.4.3. Translating Measurements into Clinical Decisions
4.2.4.4. Managing Contraindications in Special Populations
4.3. Key Trends
4.3.1. Integration of Bioimpedance into Wearables and Smart Scales
4.3.2. Body Composition as an Endpoint in Obesity Drug Development
4.3.3. Adoption of Multi-Frequency and Segmental Analysis in Clinical Practice
4.3.4. Redefinition of Obesity Around Adiposity
4.4. Technology Landscape
4.4.1. Single-Frequency, Multi-Frequency, and Segmental BIA
4.4.2. Bioimpedance Spectroscopy
4.4.3. Dual-Energy X-Ray Absorptiometry
4.4.4. Air Displacement Plethysmography
4.4.5. 3D Optical and AI-Based Body Scanning
4.4.6. Connectivity, Apps, and EHR Integration
4.5. Clinical Evidence and Guidelines
4.5.1. Lancet Commission Definition of Clinical Obesity (2025)
4.5.2. Sarcopenia Diagnostic Criteria (EWGSOP2)
4.5.3. Validation Studies Against Reference Methods
4.5.4. Body Composition in Obesity Drug Trials
4.6. Regulatory and Reimbursement Landscape
4.6.1. FDA Regulation of Body Composition Devices and General Wellness Products
4.6.2. EU Medical Device Regulation
4.6.3. Health Data Privacy Regulation
4.6.4. Reimbursement and Coding
4.7. Pricing Analysis
4.8. Value Chain Analysis
4.9. Porter's Five Forces Analysis
5. Body Composition Analyzers Market, by Technology
5.1. Introduction
5.2. Bioelectrical Impedance Analysis
5.2.1. Single-Frequency BIA
5.2.2. Multi-Frequency & Segmental BIA
5.2.3. Bioimpedance Spectroscopy
5.3. Dual-Energy X-Ray Absorptiometry
5.4. Air Displacement Plethysmography
5.5. 3D Optical Body Scanning
5.6. Skinfold Calipers & Others
6. Body Composition Analyzers Market, by Product Type
6.1. Introduction
6.2. Professional Analyzers
6.3. Portable & Handheld Analyzers
6.4. Consumer Smart Scales
7. Body Composition Analyzers Market, by Application
7.1. Introduction
7.2. Obesity & Weight Management
7.3. Sarcopenia & Clinical Nutrition
7.4. Fluid & Dialysis Management
7.5. Fitness & Sports Performance
7.6. Research & Clinical Trials
8. Body Composition Analyzers Market, by End User
8.1. Introduction
8.2. Hospitals & Clinics
8.3. Fitness Centers & Sports Organizations
8.4. Academic & Research Institutions
8.5. Pharmaceutical Companies & CROs
8.6. Home Users
9. Body Composition Analyzers Market, by Distribution Channel
9.1. Introduction
9.2. Direct Sales & Distributors
9.3. Retail & E-Commerce
10. Body Composition Analyzers Market, by Geography
10.1. Introduction
10.2. North America
10.2.1. U.S.
10.2.2. Canada
10.3. Europe
10.3.1. Germany
10.3.2. U.K.
10.3.3. France
10.3.4. Italy
10.3.5. Spain
10.3.6. Nordic Countries
10.3.7. Rest of Europe
10.4. Asia-Pacific
10.4.1. China
10.4.2. Japan
10.4.3. South Korea
10.4.4. India
10.4.5. Australia
10.4.6. Southeast Asia
10.4.7. Rest of Asia-Pacific
10.5. Latin America
10.5.1. Brazil
10.5.2. Mexico
10.5.3. Colombia
10.5.4. Argentina
10.5.5. Chile
10.5.6. Rest of Latin America
10.6. Middle East & Africa
10.6.1. Saudi Arabia
10.6.2. UAE
10.6.3. Kuwait & Qatar
10.6.4. South Africa
10.6.5. Rest of Middle East & Africa
11. Competitive Landscape
11.1. Overview
11.2. Key Growth Strategies
11.3. Competitive Benchmarking
11.4. Competitive Dashboard
11.4.1. Industry Leaders
11.4.2. Market Differentiators
11.4.3. Vanguards
11.4.4. Emerging Companies
11.5. Market Share/Rank Analysis, by Key Player (2025)
12. Company Profiles
Business Overview, Financial Overview, Product Portfolio, Strategic Developments, and SWOT Analysis
Professional Body Composition Specialists
12.1. InBody Co., Ltd.
12.2. Tanita Corporation
12.3. seca GmbH & Co. KG
12.4. COSMED S.r.l.
12.5. Akern S.r.l.
12.6. Bodystat Ltd.
12.7. RJL Systems, Inc.
12.8. Charder Electronic Co., Ltd.
12.9. SELVAS Healthcare, Inc.
Imaging and Clinical Technology Companies
12.10. Hologic, Inc.
12.11. GE HealthCare Technologies Inc.
12.12. Fresenius Medical Care AG
12.13. ImpediMed Limited
Consumer Health and Electronics Companies
12.14. Omron Healthcare Co., Ltd.
12.15. Withings
12.16. Garmin Ltd.
12.17. Xiaomi Corporation
12.18. Samsung Electronics Co., Ltd.
13. Appendix
13.1. Related Reports
13.2. Customization Options
List of Tables [282]
List of Figures [51]
For more information about this report visit https://www.researchandmarkets.com/r/g7rohy
About ResearchAndMarkets.com
ResearchAndMarkets.com is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.